ABBV-303 Is an NK-cell Engager Specific for c-Met–Expressing Tumors
ABBV-303 is a biologic that engages and potently redirects NK cells and costimulates CD8+ T cells in c-Met expressing tumors while demonstrating relative tolerance of normal tissue-derived cells.
Authors
- Stephanie Shee (ORCID: https://orcid.org/0000-0001-9871-5626)
- Lisa A. McKay (ORCID: https://orcid.org/0009-0000-3215-634X)
- Joann P. Palma (ORCID: https://orcid.org/0009-0008-9500-5002)
- Claudina Stevenson (ORCID: https://orcid.org/0009-0008-9515-9036)
- Adam S. Chervin (ORCID: https://orcid.org/0009-0007-4185-1345)
- H. David Inzunza (ORCID: https://orcid.org/0009-0006-9389-0250)
- Tamar Uziel (ORCID: https://orcid.org/0009-0005-8075-1553)
- Edward B. Reilly (ORCID: https://orcid.org/0000-0003-1999-7501)
- Jennifer D. Stone (ORCID: https://orcid.org/0000-0001-5654-5825)
- Enrico L. DiGiammarino (ORCID: https://orcid.org/0000-0001-8711-7292)
- Cormac Cosgrove (ORCID: https://orcid.org/0000-0001-7856-2984)
- Saeed Salehin Akhand (ORCID: https://orcid.org/0000-0002-4767-4761)
- Kamonwan Fish (ORCID: https://orcid.org/0009-0001-0272-5609)
- Paul A. Ellis (ORCID: https://orcid.org/0009-0005-0179-7124)
- David Peetz (ORCID: https://orcid.org/0009-0009-9196-3438)
- Devika Ashok (ORCID: https://orcid.org/0009-0008-1863-4737)
Institutions
- Purdue University West Lafayette (US)
- Bay Institute (US)
- AbbVie (United States) (US)
Publication Details
- Journal
- Cancer Research
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1158/0008-5472.can-25-0820
- Citations
- 2
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 1.59